anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Erythromycin
Trial phase: Phase 2 | Phase 3
ATC code: D10AF02 | D10AF52 | J01FA01 | S01AA17
SMILES: CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 24
Group description: Comparators were dosed up to 10 days per sites standard of care.
Eligibility criteria:
Inclusion Criteria:

History of and/or documented fever (rectal, ear, or oral temperature ≥38°C or axillary temperature ≥37.5°C) or hypothermia (rectal, ear, or oral temperature <35°C or axillary temperature <34.5°C)
Chest radiograph infiltrates consistent with bacterial pneumonia (or pneumonia caused by atypical bacterial agents); if a subject is outpatient and starting on oral therapy, a radiograph is not required.
Presence of at least 2 of the following signs or symptoms:
Cough
Difficulty breathing
Production of purulent sputum
Chest pain
Grunting
Hypotension

Tachycardia, defined as follows:

2 months to <24 months: ≥160 beats/min 24 months to <10 years: ≥140 beats/min

10 years: ≥100 beats/min

Tachypnea, defined as follows:

2 months to <12 months: ≥50 breaths/min 12 months to <5 years: ≥40 breaths/min

5 years: ≥20 breaths/min
Physical exam consistent with pulmonary consolidation
Presence of at least 1 of the following:
Leukocytosis (≥12,000 white blood cells [WBC]/mm3)
Leukopenia (<5000 WBC/mm3)
≥10% immature neutrophils (bands) regardless of total peripheral WBC
Elevated inflammatory markers (C-reactive protein or procalcitonin)
Oxygen saturation <97% on room air
Organism consistent with a typical respiratory pathogen identified

Exclusion Criteria:

Ventilator-associated or hospital-acquired pneumonia
>48 hours of systemic antibacterial therapy
confirmed or suspected bacterial meningitis
breast-feeding females
positive pregnancy test
Intervention: Acetylcysteine
Trial phase: Phase 4
ATC code: R05CB01 | S01XA08 | V03AB23
SMILES: CC(=O)N[C@@H](CS)C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 1
Group description: NAC (trade name: Mucomyst) is manufactured by American Regent. The active drug studied here is 20% NAC delivered via nebulizer three times per day for seven days.

n-acetylcystine: NAC is a mucolytic drug.
Eligibility criteria:
Inclusion Criteria:

Able to perform reproducible spirometry according to ATS criteria
Clinical history consistent with moderate to severe asthma for 1 year or greater.
Post-bronchodilator FEV1 <90% of predicted
Prescription and daily use of inhaled corticosteroid (ICS) equivalent to 240mcg of beclomethasone or greater and a second asthma controller therapy.
CT mucus score >3 (determined during the initial screening process, provided the prior two conditions are met)
Written informed consent obtained from participant and ability for participant to comply with the requirements of the study.

Exclusion Criteria:

Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study.
Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
History of intolerance to study medications.
Current use of carbamazepine
Angina which includes a treatment plan with PRN nitroglycerin or nitrites
Smoking of tobacco or other recreational inhalants in last year and/or >10 pack-year smoking history
Current participation in an investigational drug trial Concurrent Medications
Intervention: SODIUM CHLORIDE
Trial phase: Phase 4
ATC code: A12CA01 | B05CB01 | B05XA03 | S01XA03
SMILES: [Cl-].[Na+]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 1
Group description: Normal saline will be administered as the placebo agent via a nebulizer three times per day for seven days.

0.9% saline: Normal saline is a placebo agent.
Eligibility criteria:
Inclusion Criteria:

Able to perform reproducible spirometry according to ATS criteria
Clinical history consistent with moderate to severe asthma for 1 year or greater.
Post-bronchodilator FEV1 <90% of predicted
Prescription and daily use of inhaled corticosteroid (ICS) equivalent to 240mcg of beclomethasone or greater and a second asthma controller therapy.
CT mucus score >3 (determined during the initial screening process, provided the prior two conditions are met)
Written informed consent obtained from participant and ability for participant to comply with the requirements of the study.

Exclusion Criteria:

Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study.
Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
History of intolerance to study medications.
Current use of carbamazepine
Angina which includes a treatment plan with PRN nitroglycerin or nitrites
Smoking of tobacco or other recreational inhalants in last year and/or >10 pack-year smoking history
Current participation in an investigational drug trial Concurrent Medications
Intervention: Racivir
Trial phase: Phase 3
ATC code: J05AF09 | J05AR03 | J05AR06 | J05AR08 | J05AR09 | J05AR17 | J05AR18 | J05AR19 | J05AR20 | J05AR22
SMILES: Nc1nc(=O)n(C2CSC(CO)O2)cc1F
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 183
Group description: E/C/F/TAF (150/150/200/10 mg) FDC tablets administered orally once daily with food for 48 weeks
Eligibility criteria:
Key Inclusion Criteria:

HIV-infected adult participants who meet the following criteria will be given the option to participate in the study:

Currently receiving ABC/3TC plus a third antiretroviral (ARV) agent for ≥ 6 consecutive months preceding the screening visit. For subjects with 3 or more ART regimens, a regimen history must be provided to the Sponsor for approval. Allowed third antiretroviral agents include LPV/r, ATV+RTV, ATV+COBI (or ATV/COBI FDC), DRV+RTV, DRV + COBI (or DRV/COBI FDC) FPV + RTV, SQV + RTV, ATV (no booster), EFV, RPV, NVP, ETR, RAL or DTG
Documented plasma HIV-1 RNA levels < 50 copies/mL for ≥ 6 months preceding the screening visit (measured at least twice using the same assay). In the preceding 6 months prior to screening, one episode of "blip" (HIV-1 RNA > 50 and < 400 copies/mL) is acceptable, only if HIV-1 RNA is < 50 copies/mL immediately before and after the "blip".
Plasma HIV-1 RNA < 50 copies/mL at screening visit
Individuals will have no evidence of previous virologic failure on a PI+RTV or integrase strand transfer inhibitor-based regimen (with or without resistance to either class of ARV).
All documented historical plasma genotype(s) must not show resistance to tenofovir disoproxil fumarate (TDF) or emtricitabine (FTC), including, but not limited to the presence of reverse transcriptase resistance mutants K65R, K70E, M184V/I, or thymidine analog associated mutations (TAMs) (TAMs are: M41L, D67N, K70R, L210W, T215Y/F, K219Q/E/N/R). If a historical genotype is not available or subject has 3 or more ART regimens, subject will have proviral genotype analysis prior to Day 1 to confirm absence of archived resistance to TDF or FTC.
Adequate renal function defined as having an estimated glomerular filtration rate of ≥ 30 mL/min as calculated by Cockcroft-Gault (eGFR-CG)

Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Intervention: Metolazone
Trial phase: Phase 4
ATC code: C03BA08 | C03EA12 | G01AE10
SMILES: Cc1ccccc1N1C(=O)c2cc(S(N)(=O)=O)c(Cl)cc2NC1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 20
Group description: Metolazone 5mg tablet orally twice daily for 48 hours.
Eligibility criteria:
Inclusion Criteria:

age of 18 years or older
hospital admission for hypervolemic decompensated heart failure complicated by loop diuretic resistance
24 hour telemetry monitoring on an inpatient ward
basic metabolic panel laboratory assessment twice daily during the study period

Hypervolemia will be diagnosed by the admitting provider as either (i) pulmonary artery catheterization with a pulmonary capillary wedge pressure greater than 19mmHg plus a systemic physical exam finding of hypervolemia (peripheral edema, ascites, or pulmonary edema on auscultation) or (ii) in the absence of pulmonary artery catheterization data 2 of the following signs or symptoms: peripheral edema ascites, jugular venous pressure > 10mmHg, or pulmonary edema on chest x-ray.

Loop diuretic resistance is defined as a provider decision to pursue combination diuretic therapy because of failure to reach provider defined adequate diuresis (can not exceed urine output of 2 L in past 12 hours) despite receipt of an intravenous loop diuretic dose of a furosemide equivalent of at least 240mg/day over at least the past 12 hours (40mg furosemide = 20mg torsemide = 1mg bumetanide).

Exclusion Criteria:

decision to pursue hemodialysis by a nephrologist
estimated glomerular filtration rate by the MDRD equation < 15ml/min/m2
systolic blood pressure < 85mmHg
pregnancy
serum potassium < 3.0mEq/L
serum sodium > 145mEq/L or < 130mEq/L
severe malnutrition
advanced liver disease
inability to perform standing weights
inability to collect and measure urine with either a foley catheter or urine collection containers
concomitant therapy with strong CYP3A4 inhibitors/inducers (systemic ketoconazole, clarithromycin, itraconazole, telithromycin, saquinavir, nelfinavir, ritonavir, nefazodone, rifampin, rifabutin, rifapentine, phenytoin, phenobarbital, carbamazepine, St. John's Wort)
concomitant therapy with p-glycoprotein inhibitors (cyclosporine, erythromycin, tacrolimus, dronedarone, quinidine, or verapamil)
non-study diuretics (spironolactone doses >75mg/day, eplerenone > 75mg/day, non-study thiazides or loop diuretics, or systemic acetazolamide, triamterene, or amiloride therapy)
thiazides administration in the previous 24 hours prior to randomization
Intervention: Chlorothiazide
Trial phase: Phase 4
ATC code: C03AA04 | C03AB04 | C03AH01 | G01AE10
SMILES: NS(=O)(=O)c1cc2c(cc1Cl)NC=NS2(=O)=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 20
Group description: Chlorothiazide 500mg intravenous infusion over 30 minutes twice daily for 48 hours
Eligibility criteria:
Inclusion Criteria:

age of 18 years or older
hospital admission for hypervolemic decompensated heart failure complicated by loop diuretic resistance
24 hour telemetry monitoring on an inpatient ward
basic metabolic panel laboratory assessment twice daily during the study period

Hypervolemia will be diagnosed by the admitting provider as either (i) pulmonary artery catheterization with a pulmonary capillary wedge pressure greater than 19mmHg plus a systemic physical exam finding of hypervolemia (peripheral edema, ascites, or pulmonary edema on auscultation) or (ii) in the absence of pulmonary artery catheterization data 2 of the following signs or symptoms: peripheral edema ascites, jugular venous pressure > 10mmHg, or pulmonary edema on chest x-ray.

Loop diuretic resistance is defined as a provider decision to pursue combination diuretic therapy because of failure to reach provider defined adequate diuresis (can not exceed urine output of 2 L in past 12 hours) despite receipt of an intravenous loop diuretic dose of a furosemide equivalent of at least 240mg/day over at least the past 12 hours (40mg furosemide = 20mg torsemide = 1mg bumetanide).

Exclusion Criteria:

decision to pursue hemodialysis by a nephrologist
estimated glomerular filtration rate by the MDRD equation < 15ml/min/m2
systolic blood pressure < 85mmHg
pregnancy
serum potassium < 3.0mEq/L
serum sodium > 145mEq/L or < 130mEq/L
severe malnutrition
advanced liver disease
inability to perform standing weights
inability to collect and measure urine with either a foley catheter or urine collection containers
concomitant therapy with strong CYP3A4 inhibitors/inducers (systemic ketoconazole, clarithromycin, itraconazole, telithromycin, saquinavir, nelfinavir, ritonavir, nefazodone, rifampin, rifabutin, rifapentine, phenytoin, phenobarbital, carbamazepine, St. John's Wort)
concomitant therapy with p-glycoprotein inhibitors (cyclosporine, erythromycin, tacrolimus, dronedarone, quinidine, or verapamil)
non-study diuretics (spironolactone doses >75mg/day, eplerenone > 75mg/day, non-study thiazides or loop diuretics, or systemic acetazolamide, triamterene, or amiloride therapy)
thiazides administration in the previous 24 hours prior to randomization
Intervention: Tolvaptan
Trial phase: Phase 4
ATC code: C03XA01
SMILES: Cc1ccccc1C(=O)Nc1ccc(C(=O)N2CCCC(O)c3cc(Cl)ccc32)c(C)c1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 20
Group description: Tolvaptan 30mg tablet orally once daily for 48 hours
Eligibility criteria:
Inclusion Criteria:

age of 18 years or older
hospital admission for hypervolemic decompensated heart failure complicated by loop diuretic resistance
24 hour telemetry monitoring on an inpatient ward
basic metabolic panel laboratory assessment twice daily during the study period

Hypervolemia will be diagnosed by the admitting provider as either (i) pulmonary artery catheterization with a pulmonary capillary wedge pressure greater than 19mmHg plus a systemic physical exam finding of hypervolemia (peripheral edema, ascites, or pulmonary edema on auscultation) or (ii) in the absence of pulmonary artery catheterization data 2 of the following signs or symptoms: peripheral edema ascites, jugular venous pressure > 10mmHg, or pulmonary edema on chest x-ray.

Loop diuretic resistance is defined as a provider decision to pursue combination diuretic therapy because of failure to reach provider defined adequate diuresis (can not exceed urine output of 2 L in past 12 hours) despite receipt of an intravenous loop diuretic dose of a furosemide equivalent of at least 240mg/day over at least the past 12 hours (40mg furosemide = 20mg torsemide = 1mg bumetanide).

Exclusion Criteria:

decision to pursue hemodialysis by a nephrologist
estimated glomerular filtration rate by the MDRD equation < 15ml/min/m2
systolic blood pressure < 85mmHg
pregnancy
serum potassium < 3.0mEq/L
serum sodium > 145mEq/L or < 130mEq/L
severe malnutrition
advanced liver disease
inability to perform standing weights
inability to collect and measure urine with either a foley catheter or urine collection containers
concomitant therapy with strong CYP3A4 inhibitors/inducers (systemic ketoconazole, clarithromycin, itraconazole, telithromycin, saquinavir, nelfinavir, ritonavir, nefazodone, rifampin, rifabutin, rifapentine, phenytoin, phenobarbital, carbamazepine, St. John's Wort)
concomitant therapy with p-glycoprotein inhibitors (cyclosporine, erythromycin, tacrolimus, dronedarone, quinidine, or verapamil)
non-study diuretics (spironolactone doses >75mg/day, eplerenone > 75mg/day, non-study thiazides or loop diuretics, or systemic acetazolamide, triamterene, or amiloride therapy)
thiazides administration in the previous 24 hours prior to randomization
Intervention: Valsartan
Trial phase: Not Applicable
ATC code: C09CA03 | C09DA03 | C09DB01 | C09DB08 | C09DX01 | C09DX02 | C09DX04 | C09DX05 | C10BX10
SMILES: CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1)[C@H](C(=O)O)C(C)C
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 1
Group description: 20 HIV-infected participants will be randomized into a blinded arm where they receive 24 weeks of valsartan therapy. For those subjects randomized to the valsartan group, they will receive valsartan 40 mg by mouth daily for 2 weeks, then increase to 80 mg by mouth daily for the remaining 22 weeks. During this time, they will undergo the same study procedures as the placebo arm.

valsartan: Valsartan will be given in increasing doses (from 40 mg to 80 mg) to those in the valsartan arm.
Eligibility criteria:
Inclusion Criteria:

able to provide informed consent
able to attend an extended (~4 hour) Clinical Research Visit
documented HIV seropositivity
on a stable anti-retroviral therapy (ART) regimen for at least 12 months
HIV plasma viral load < 50 copies/ml for at least 6 months
Systolic blood pressure >110

Exclusion Criteria:

creatinine > 1.5 ULN (or creatinine clearance < 60 ml/min)
anti-hypertensive therapy with ACE-I or AT1R-blockers
inability to perform functional measures (e.g. non-ambulatory without assistance, requires a prosthesis)
recent (within 30 days) acute illness requiring medical therapy or hospitalization
immunosuppressive agents (e.g. > 20 mg/d x 2 or more weeks of prednisone or equivalent, chemotherapy) in the last 6 months
cancer requiring treatment w/in 3 yrs (except for non-melanoma skin cancer)
blood thinning medications such as Coumadin or Plavix or a bleeding disorder such as hemophilia that could cause complications during muscle biopsies
pregnancy (will provide urine test for females of child bearing potential)
regular use of non-steroidal anti-inflammatory drugs or other immune modulating agents.
Intervention: Vancomycin
Trial phase: Phase 3
ATC code: A07AA09 | J01XA01 | S01AA28
SMILES: CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 302
Group description: vancomycin 15 mg/kg intravenous every 12, 24 or 48 hours based on creatinine clearance

Vancomycin: Active comparator
Eligibility criteria:
Inclusion Criteria:

written informed consent;
≥18 years of age;
a bacterial infection of the skin with a lesion size area of at least 75 cm2;
a major cutaneous abscess, cellulitis/erysipelas, and/or wound infections;
the presence of purulent or seropurulent drainage or at least three signs and symptoms of infection (discharge, erythema, swelling, warmth, or pain).

Exclusion Criteria:

severely impaired arterial blood supply such that amputation of the infected anatomical site is likely;
infected diabetic foot ulcers;
infected decubitus ulcers;
necrotizing fasciitis or gangrene;
uncomplicated skin or skin structure infection;
infections associated with a prosthetic device;
suspected or confirmed osteomyelitis;
conditions requiring systemic anti-microbial treatment, prophylaxis, or suppression therapy.
Intervention: Velpatasvir
Trial phase: Phase 3
ATC code: J05AP55 | J05AP56
SMILES: COC[C@H]1C[C@@H](c2nc(-c3ccc4c(c3)COc3cc5c(ccc6nc([C@@H]7CC[C@H](C)N7C(=O)[C@@H](NC(=O)OC)C(C)C)[nH]c65)cc3-4)c[nH]2)N(C(=O)[C@H](NC(=O)OC)c2ccccc2)C1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 263
Group description: SOF/VEL/VOX (400/100/100 mg) FDC tablet orally once daily with food for 12 weeks
Eligibility criteria:
Key Inclusion Criteria:

Willing and able to provide written informed consent
HCV RNA ≥ 10^4 IU/mL at screening
Chronic HCV infection (≥ 6 months)
Treatment experienced with a direct acting antiviral medication for HCV
Use of protocol specified methods of contraception

Key Exclusion Criteria:

Current or prior history of clinically significant illness that may interfere with participation in the study
Screening ECG with clinically significant abnormalities
Laboratory results outside of acceptable ranges at screening
Pregnant or nursing female
Chronic liver disease not caused by HCV
Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)

Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Intervention: Velpatasvir
Trial phase: Phase 3
ATC code: J05AP55 | J05AP56
SMILES: COC[C@H]1C[C@@H](c2nc(-c3ccc4c(c3)COc3cc5c(ccc6nc([C@@H]7CC[C@H](C)N7C(=O)[C@@H](NC(=O)OC)C(C)C)[nH]c65)cc3-4)c[nH]2)N(C(=O)[C@H](NC(=O)OC)c2ccccc2)C1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 147
Group description: Participants who completed placebo treatment were eligible for open-label Deferred Treatment Substudy.

SOF/VEL/VOX (400/100/100 mg) FDC tablet orally once daily with food for 12 weeks
Eligibility criteria:
Key Inclusion Criteria:

Willing and able to provide written informed consent
HCV RNA ≥ 10^4 IU/mL at screening
Chronic HCV infection (≥ 6 months)
Treatment experienced with a direct acting antiviral medication for HCV
Use of protocol specified methods of contraception

Key Exclusion Criteria:

Current or prior history of clinically significant illness that may interfere with participation in the study
Screening ECG with clinically significant abnormalities
Laboratory results outside of acceptable ranges at screening
Pregnant or nursing female
Chronic liver disease not caused by HCV
Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)

Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Intervention: Velpatasvir
Trial phase: Phase 3
ATC code: J05AP55 | J05AP56
SMILES: COC[C@H]1C[C@@H](c2nc(-c3ccc4c(c3)COc3cc5c(ccc6nc([C@@H]7CC[C@H](C)N7C(=O)[C@@H](NC(=O)OC)C(C)C)[nH]c65)cc3-4)c[nH]2)N(C(=O)[C@H](NC(=O)OC)c2ccccc2)C1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 440
Group description: SOF/VEL (400/100 mg) FDC tablet orally once daily with or without food for 12 weeks
Eligibility criteria:
Key Inclusion Criteria:

Willing and able to provide written informed consent
HCV RNA ≥ 10^4 IU/mL at screening
Chronic HCV infection (≥ 6 months)
HCV treatment naive or treatment experienced with an interferon (IFN)-based regimen
Use of protocol specified methods of contraception

Key Exclusion Criteria:

Current or prior history of clinically significant illness that may interfere with participation in the study
Screening ECG with clinically significant abnormalities
Laboratory parameters outside the acceptable range at screening
Pregnant or nursing female
Chronic liver disease not caused by HCV
Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)

Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Intervention: Diquafosol
Trial phase: Not Applicable
SMILES: O=c1ccn([C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@H]3O[C@@H](n4ccc(=O)[nH]c4=O)[C@H](O)[C@@H]3O)[C@@H](O)[C@H]2O)c(=O)[nH]1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 31
Group description: 3% Diquafosol Tetrasodium Ophthalmic Solution

Diquafosol (Diquas): Diquafosol group used diquafosol 6 times a day during study period.
Eligibility criteria:
Inclusion Criteria:

Bilateral or unilateral cataract undergoing phacoemulsification and intraocular lens (IOL) implantation at Soonchunhyang University Hospital between January 2014 and January 2015
Patients with mild to moderate dry eye (level 1 or 2) based on the dry eye severity scale adopted by the Dry Eye Workshop (DEWS) report and who used only artificial tears occasionally

Exclusion Criteria:

Presence of any complications after cataract surgery such as cystoid macular edema
Patients using any topical eye drops on a regular basis
Treatment history of dry eye beyond artificial tears
Any ocular surgery within the prior 6 months
Contact lens wear
Serious ocular surface disease (e.g., Sjögren's syndrome, ocular pemphigoid, conjunctival scarring, chemical injury)
Eyelid or lacrimal disease
Use of concomitant medications that could cause dry eye and allergy to any of the study medications